EP1654255B1 - Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors - Google Patents

Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors Download PDF

Info

Publication number
EP1654255B1
EP1654255B1 EP04754066A EP04754066A EP1654255B1 EP 1654255 B1 EP1654255 B1 EP 1654255B1 EP 04754066 A EP04754066 A EP 04754066A EP 04754066 A EP04754066 A EP 04754066A EP 1654255 B1 EP1654255 B1 EP 1654255B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
halo
aryl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04754066A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1654255A1 (en
Inventor
Han-Cheng Zhang
Bruce E. Maryanoff
Hong Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP1654255A1 publication Critical patent/EP1654255A1/en
Application granted granted Critical
Publication of EP1654255B1 publication Critical patent/EP1654255B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • This invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase or dual-kinase mediated disorder. More particularly, this invention is directed to indazolyl-substituted pyrroline compounds useful as selective kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
  • R 1 signifies hydrogen, alkyl, aryl (limited to phenyl), aralkyl (limited to phenylalkyl), alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, trialkylaminoalkyl, aminoalkylaminoalkyl, azidoalkyl, acylaminoalkyl, acylthioalkyl, alkylsulphonylaminoalkyl, arylsulphonylaminoalkyl, mercaptoalkyl, alkylthioalkyl, alkylsulphinylalkyl, alkylsulphonylalkyl, alkylsulphonyloxyalkyl, alkylcarbonyloxyalkyl, cyano
  • novel compounds of the present invention are structurally unlike those disclosed by the Davis 5,057,614 patent.
  • the Davis 5,057,614 patent discloses indolyl substituted pyrrole compounds of formula I which may be further substituted on the R 3 position with a carbocyclic or heterocyclic aromatic group.
  • the carbocyclic aromatic group denoted by R 3 can be a monocyclic or polycyclic group, preferably a monocyclic or bicyclic group, i.e.
  • phenyl or naphthyl which can be substituted or unsubstituted, for example, with one or more, preferably one to three, substituents selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, monoalkylamino, dialkylamino, alkylthio, alkylsulphinyl and alkylsulphonyl.
  • examples of carbocyclic aromatic groups denoted in the Davis '614 patent by R 3 are phenyl, 2-, 3-, or 4-chlorophenyl, 3-bromophenyl, 2- or 3-methylphenyl, 2,5-dimethylphenyl, 4-methoxyphenyl, 2- or 3-trifluoromethylphenyl, 2-, 3-, or 4-nitrophenyl, 3-, or 4-aminophenyl, 4-methylthiophenyl, 4-methylsulphinylphenyl, 4-methylsulphonylphenyl and 1-, or 2-naphthyl.
  • the heterocyclic aromatic group denoted by R 3 can be a 5- or 6-membered heterocyclic aromatic group which can optionally carry a fused benzene ring and which can be substituted or unsubstituted, for example, with one or more, preferably one to three, substituents selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, mono- or dialkylamino, alkylthio, alkylsulphinyl and alkylsulphonyl.
  • heterocyclic aromatic groups denoted in the Davis '614 patent by R 3 are 2-, or 3-thienyl, 3-benzothienyl, 1-methyl-2-pyrrolyl, 1-benzimidazolyl, 3-indolyl, 1- or 2-methyl-3-indolyl, 1-methoxymethyl-3-indolyl, 1-(1-methoxyethyl)-3-indolyl, 1-(2-hydroxypropyl)-3-indolyl, 1-(4-hydroxybutylh3-indolyl, 1-[1-(2-hydroxyethylthio)ethyl]-3-indolyl, 1-[1-(2-mercaptoethylthio)ethyl]-3-indoly), 1-(1-phenylthioethyl)-3-indolyl, 1-[1-(carboxymethylthio)ethyl]-3-indolyl and 1-benzyl
  • novel compounds of the present invention are structurally unlike those disclosed by the Davis 5,721,245 patent.
  • the Davis 5,721,245 patent discloses 4-[3-indolyl]-1 H-pyrrolone compounds of formula I which may be further substituted on the R 3 position with an aryl or aromatic heterocyclic group.
  • aryl denotes a monocyclic or polycyclic group, preferably a monocyclic or bicyclic group, for example, phenyl or naphthyl, which can be substituted or unsubstituted, for example, with one or more, preferably one to three, substituents selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl and alkylsulfonyl.
  • examples of such aryl groups in the Davis 245 patent are phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 2-methylphenyl, 3-methylphenyl, 2,5-dimethylphenyl, 4-methoxyphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-aminophenyl, 4-aminophenyl, 4-methylthiophenyl, 4-methylsulfinylphenyl, 4-methylsulfonylphenyl, 1-naphthyl, 2-naphthyl and the like.
  • aromatic heterocyclic means a 5- or 6-membered heterocyclic aromatic group which can optionally carry a fused benzene ring and which can be substituted or unsubstituted, for example, with one or more, preferably one to three, substituents selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl and alkylsulfonyl.
  • heterocyclic groups in the Davis '245 patent are 2-thienyl, 3-thienyl, 3-benzothienyl, 3-benzofuranyl, 2-pyrrolyl, 3-indolyl and the like which can be unsubstituted or substituted in the manner indicated.
  • the 5- or 6-membered saturated nitrogen containing heterocycle attached via the nitrogen atom can contain an additional nitrogen or oxygen or a sulfur atom, examples of such heterocycles are pyrrolidino, piperidino, piperazino, morpholino and thiomorpholino.
  • Patent application WO 00/06564 discloses disubstituted maleimide compounds of Formula (I): wherein R 1 represents hydrogen or alkyl; R 2 represents aryl, cycloalkyl or a heterocycle; R 3 , R 5 , R 6 , R 7 and R 8 represent each hydrogen, halogen, hydroxy, amino, alkyl or alkoxy; and R 4 is W, or R 4 and R 3 or R 4 and R 5 may form together a ring substituted by W thereon; wherein W represents -(CH2) l -(Y) m -(CH2) n -Z as PKC ⁇ inhibitors.
  • R 1 represents hydrogen or alkyl
  • R 2 represents aryl, cycloalkyl or a heterocycle
  • R 3 , R 5 , R 6 , R 7 and R 8 represent each hydrogen, halogen, hydroxy, amino, alkyl or alkoxy
  • R 4 is W, or R 4 and R 3 or R 4 and R 5 may form together
  • Patent application WO 00/21927 describes 3-amino-4-arymaleimide compounds having formula (I): or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl or aralkyl; R 1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R 2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R 3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R 1 and R 3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocyclic ring and a method for the treatment of conditions associated with a need for inhibition of
  • indazolyl-substituted pyrroline compounds of the present invention have not been heretofore disclosed.
  • indazolyl-substituted pyrroline compounds useful as a kinase or dual-kinase inhibitor in particular, a kinase selected from protein kinase C or glycogen synthase kinase-3; and, more particularly, a kinase selected from protein kinase C ⁇ , protein kinase C ⁇ (e.g.
  • protein kinase C ⁇ -I and protein kinase C ⁇ -II protein kinase C ⁇ or glycogen synthase kinase-3 ⁇
  • methods for their production and methods for treating or ameliorating a kinase or dual-kinase mediated disorder are included in the production of kinase or dual-kinase mediated disorder.
  • the present invention is directed to indazolyl-substituted pyrroline compounds of Formula (I) wherein
  • the present invention is directed to indazolyl-substituted pyrroline compounds useful as a selective kinase or dual-kinase inhibitor; in particular, a kinase selected from protein kinase C or glycogen synthase kinase-3; and, more particularly, a kinase selected from protein kinase C ⁇ , protein kinase C ⁇ (e.g. protein kinase C ⁇ Iand protein kinase C ⁇ -II), protein kinase C ⁇ or glycogen synthase kinase3 ⁇ .
  • a kinase selected from protein kinase C or glycogen synthase kinase-3 e.g. protein kinase C ⁇ Iand protein kinase C ⁇ -II
  • protein kinase C ⁇ or glycogen synthase kinase3 ⁇ e.g. protein kinas
  • the present invention is also directed to methods for producing the instant indazolyl-substituted pyrroline compounds and pharmaceutical compositions and medicaments thereof.
  • the present invention is further directed to methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
  • the method of the present invention is directed to treating or ameliorating a kinase or dual-kinase mediated disorder such as, but not limited to, cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and CNS disorders.
  • Preferred embodiments of the present invention include compounds of Formula (I) wherein, R 1 isselected from the group consisting of:
  • R 1 is selected from the group consisting of:
  • Preferred embodiments of the present invention include compounds of Formula (I) wherein, R 1 is selected from the group consisting of
  • R 1 is selected from the group consisting of
  • R 2 is alkynyl-Z
  • the unsaturated bond(s) in the alkynyl will not be directly linked to a nitrogen atom on Z or the indazolyl of Formula I.
  • Preferred embodiments of the present invention include compounds of Formula (I) wherein, R 2 is selected from the group consisting of:
  • R 2 is selected from the group consisting of: -C 1-4 alkyl-Z wherein the -C 1-4 alkyl is optionally substituted with one to two substituents independently selected from the group consisting of halo, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 )alkylamino, C 1-4 alkyl, C 1-4 alkoxy, (halo) 1-3 (C 1-4 )alkyl, (halo) 1-3 (C 1-4 )alkoxy and hydroxy(C 1-4 )alkyl.
  • Preferred embodiments of the present invention include compounds of Formula I wherein Z is a 5 to 6 member monocyclic heteroaryl ring having from 2 to 4 heteroatoms containing at least one carbon atom and at least one nitrogen atom selected from the group consisting of pyrazine, pyrimidine, imidazol, pyridazine, triazine, furazan, isoxazole, isothiazole, thiazole, isothiazole, triazole, oxatriazole and tetrazole.
  • Z is selected from the group consisting of imidazol, triazole, oxatriazole and tetrazole.
  • Z is selected from the group consisting of oxatriazole and tetrazole.
  • Preferred embodiments of the present invention include compounds of Formula I wherein R 5 is 1 to 2 substituents attached to a carbon or nitrogen atom of Z and each substitute is independently selected from the group consisting of hydrogen, -C 1-4 alkyl, -C 2-4 alkenyl, -C 2-4 alkynyl, -C(O)H, , -C(O)-(C 1-4 )alkyl, -CO 2 H, -C(O)-O-(C 1-4 )alkyl, -C(O)-NH 2 , -C(NH)-NH 2 , -C(O)-NH(C 1-4 alkyl), -C(O)-N(C 1-4 )alkyl) 2 , -SO 2 -(C 1-4 )alkyl, -SO 2 -NH 2 , -SO2-NH(C 1-4 alkyl), -SO 2 -N(C 1-4 alkyl) 2 , -(C 1-4
  • R 5 is 1 to 2 substituents attached to a carbon or nitrogen atom of Z and each substitute is independently selected from the group consisting of -C 1-4 alkyl, -C 2-4 ,alkenyl, -(C 1-4 )alkyl-NH 2 , -(C 1-4 )alkyl-NH(C 1-4 alkyl), -(C 1-4 )alkyl- N(C 1-4 alkyl) 2 , -(C 1-4 )alkyl-(halo) 1-3 , -(C 1-4 )alkyl-OH, -(C 1-4 )alkyl-aryl, heteroaryl and -(C 1-4 )alkyl-heteroaryl; with the proviso that, when R 5 is attached to a carbon atom, R 5 is further selected from the group consisting of -C 1-4 alkoxy, -(C 1-4 )alkoxy-(halo) 1-3 , -S-(C 1-4 )
  • R 5 is -C 1-4 alkyl.
  • Preferred embodiments of the present invention include compounds of Formula I wherein R 6 is 1 to 2 substituents independently selected from the group consisting of hydrogen, -C 1-4 alkyl, -C 2-4 alkenyl, -C 2-4 alkynyl, - C 3-4 cycloalkyl, -C(O)H, -C(O)-(C 1-4 )alkyl., -C(O)-O-(C 1-4 )alkyl, -C(O)NH 2 , -C(O)-NH(C 1-4 alkyl), -C(O)-N(C 1-4 alkyl) 2 , -SO 2 -(C 1-4 )alkyl, -SO 2 -NH 2 , -SO 2 -NH(C 1-4 alkyl), -SO 2 -N(C 1-4 )alkyl) 2 , -C(N)-NH(C 1-4 alkyl) and
  • Preferred embodiments of the present invention include compounds of Formula (I) wherein, R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, -C(O)H, -C(O)-(C 1-4 )alkyl, -CO 2 H, -C(O)-O-(C 1-4 )alkyl, -C(O)-NH 2 , -C(NH)-NH 2 , -C(O)-NH-(C 1-4 )alkyl, -C(O)-N[(C 1-4 )alkyl] 2 , -SH, -S-(C 1-4 )alkyl, -SO 2 -(C 1-4 )alkyl, -SO 2 -NH 2 , -SO 2 -NH-(C 1-4 )alkyl, -SO 2 -N[(C 1-4 )
  • R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 1-4 alkoxy, cyano and halogen.
  • R 3 and R 4 are independently selected from the group consisting of hydrogen, methyl, methoxy, cyano and chloro.
  • Exemplified compounds of Formula (I) include compounds selected from Formula (Ia) (N1 and N2 for the R 2 substituent indicate that R 2 is attached to the N1- or N2-position of the indazole ring, respectively): No. R 1 R 2 R 3 R 4 ES-MS m/z (MH + ) 1 Me N1-[imidazol-1-yl(CH 2 ) 3 ] H 5-Cl; 485 2 Me N1-[triazol-1-yl(CH 2 ) 3 ] H 5-Cl; 486 681140 3 Me N1-[tetrazol-2-yl(CH 2 ) 3 ] H 5-Cl; 487 681142 4 Me N1-[tetrazol-1-yl(CH 2 ) 3 ] H 5-Cl; 487 18018338 5 2-naphthyl N1-[tetrazol-2-yl(CH 2 ) 3 ] H H; 565 18018351 6 2-naphthyl N1
  • the compounds of the present invention may also be present in the form of pharmaceutically acceptable salts.
  • the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts.”
  • FDA approved pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable acidic/anionic salts include, and are not limited to acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobioriate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate, polygalacturonate,
  • Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, meglumine, potassium, procaine, sodium and zinc. Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts.
  • Organic or inorganic acids also include, and are not limited to, hydriodic, perchloric, sulfuric, phosphoric, propionic, glycolic, methanesulfonic, hydroxyethanesulfonic, oxalic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, saccharinic or trifluoroacetic acid.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in " Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985 .
  • the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form or individual enantiomers may be prepared by standard techniques known to those skilled in the art, for example, by enantiospecific synthesis or resolution, formation of diastereomeric pairs by salt formation with an optically active acid, followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 ; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991 .
  • the protecting groups may be removed at a convenient subsequent stage using methods known in the art.
  • crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention.
  • some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.
  • alkyl refers to a saturated straight or branched chain consisting solely of 1-8 hydrogen substituted carbon atoms; preferably, 1-6 hydrogen substituted carbon atoms; and, most preferably, 1-4 hydrogen substituted carbon atoms.
  • alkenyl refers to a partially unsaturated straight or branched chain consisting solely of 2-8 hydrogen substituted carbon atoms that contains at least one double bond.
  • alkynyl refers to a partially unsaturated straight or branched chain consisting solely of 2-8 hydrogen substituted carbon atoms that contains at least one triple bond.
  • alkoxy refers to -O-alkyl, where alkyl is as defined supra.
  • hydroxyalkyl refers to radicals wherein the alkyl chain terminates with a hydroxy radical of the formula HO-alkyl, where alkyl is as defined supra.
  • Alkyl, alkenyl and alkynyl chains are optionally substituted within the alkyl chain or on a terminal carbon atom.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic alkyl ring consisting of 3-8 hydrogen substituted carbon atoms or a saturated or partially unsaturated bicyclic ring consisting of 9 or 10 hydrogen substituted carbon atoms. Examples include, and are not limited to, cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • heterocyclyl refers to an unsubstituted or substituted stable three to seven member monocyclic saturated or partially unsaturated ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O or S, or a stable eight to eleven member bicyclic saturated or partially saturated ring system which consists of carbon atoms and from one to four heteroatoms selected from N, O, or S.
  • the nitrogen or sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • saturated or partially unsaturated rings having five or six members of which at least one member is a N, O or S atom and which optionally contains one additional N, O or S atoms; saturated or partially unsaturated bicyclic rings having nine or ten members of which at least one member is a N, O or S atom and which optionally contains one or two additional N, O or S atoms; wherein said nine or ten member bicyclic rings may have one aromatic ring and one nonaromatic ring.
  • the previously defined heterocyclyl have as the additional heteroatom N, wherein at most two nitrogens atoms are adjacent.
  • Examples include, and are not limited to, pyrrolinyl, pyrrolidinyl, 1 ,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolidinyl, piperidinyl, morpholinyl or piperazinyl.
  • aryl refers to an aromatic monocyclic ring containing carbon and hydrogen, such as a carbon ring containing 6 carbon atom with hydrogen atoms substituted thereon, an aromatic bicyclic ring system containing 10 carbon atoms with hydrogen substituted thereon or an aromatic tricyclic ring system containing 14 carbon atoms with hydrogen atoms substituted thereon. Also included within the scope of the definition of aryl are bicyclic and tricyclic ring systems (containing carbon and hydrogen) wherein only one of the rings is aromatic such as tetrahydronaphthalene and indane.
  • the hydrogen atoms on the monocyclic, bicyclic and tricyclic rings may be replaced with other groups or subsitutents as indicated. Examples include, and are not limited to, phenyl, naphthalenyl or anthracenyl.
  • heteroaryl represents an unsubstituted or substituted stable five or six member monocyclic heteroaromatic ring system or an unsubstituted or substituted stable nine or ten member bicyclic heteroaromatic ring system and unsubstituted or substituted stable twelve to fourteen member tricyclic ring systems which consists of carbon atoms and from one to four heteroatoms selected from N, O or S, and wherein the nitrogen heteroatom of any of these heteroaryls may optionally be oxidized, or may optionally be quaternized.
  • Preferred heteroaryl are aromatic monocyclic rings containing five members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic monocyclic ring having six members of which one, two or three members are a N atoms; an aromatic bicyclic ring having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic bicyclic ring having ten members of which of which one, two, three or four members are N atoms; or, an aromatic tricyclic ring system containing 13 members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms.
  • the previously defined heteroaryls have as the additional heteroatom N, wherein at most four nitrogens atoms are adjacent.
  • Examples include, and are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, triazolyl, oxatriazole, tetrazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazine, indolyl, indazolyl, benzo(b)thienyl, quinolinyl, isoquinolinyl or quinazolinyl.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aralkyl, alkylamino) it shall be interpreted as including those limitations given above for "alkyl” and "aryl.”
  • Designated numbers of carbon atoms e.g., C 1 -C 6 ) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • phenylC 1-6 alkylamidoC 1-6 alkyl refers to a group of the formula:
  • a substituent's point of attachment may also be indicated by a dashed line to indicate the point(s) of attachment, followed by the adjacent functionality and ending with the terminal functionality such as, for example,_-(C 1-6 )alkyl-C(O)NH-(C 1-6 )alkyl-phenyl.
  • An embodiment of the invention is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compounds described above.
  • Illustrative of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier.
  • Another illustration of the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.
  • Further illustrative of the present invention are pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
  • the compounds of the present invention are selective kinase or dual-kinase inhibitors useful in a method for treating or ameliorating a kinase or dual-kinase mediated disorder.
  • the kinase is selected from protein kinase C or glycogen synthase kinase-3. More particularly, the kinase is selected from protein kinase C ⁇ , protein kinase C ⁇ -II, protein kinase C ⁇ or glycogen synthase kinase-3 ⁇ .
  • Protein kinase C is known to play a key role in intracellular signal transduction (cell-cell signaling), gene expression and in the control of cell differentiation and growth.
  • the PKC family is composed of twelve isoforms that are further classified into 3 subfamilies: the calcium dependent classical PKC isoforms alpha ( ⁇ ), beta-I ( ⁇ -I), beta-II ( ⁇ -II) and gamma ( ⁇ ); the calcium independent PKC isoforms delta ( ⁇ ), epsilon ( ⁇ ), eta ( ⁇ ), theta ( ⁇ ) and mu ( ⁇ ); and, the atypical PKC isoforms zeta ( ⁇ ), lambda ( ⁇ ) and iota (i).
  • PKC vascular endothelial growth factor
  • the human vitamin D receptor has been shown to be selectively phosphorylated by PKC ⁇ . This phosphorylation has been linked to alterations in the functioning of the receptor ( Hsieh, et al., Proc. Natl. Acad.
  • PKC activity plays an important role in cardiovascular diseases. Increased PKC activity in the vasculature has been shown to cause increased vasoconstriction and hypertension ( Bilder, G. E., et al., J. Pharmacol. Exp. Ther., 1990, 252, 526-530 ). PKC inhibitors block agonist-induced smooth muscle cell proliferation ( Matsumoto, H. and Sasaki, Y., Biochem. Biophys. Res. Commun., 1989, 158, 105-109 ).
  • PKC ⁇ triggers events leading to induction of Egr-1 (Early Growth Factor-1) and tissue factor under hypoxic conditions (as part of the oxygen deprivation-mediated pathway for triggering procoagulant events) ( Yan, S-F, et al., J. Biol. Chem., 2000, 275, 16, 11921-11928 ).
  • PKC ⁇ is suggested as a mediator for production of PAI-1 (Plaminogen Activator Inhibitor-1) and is implicated in the development of thrombosis and atherosclerosis ( Ren, S, et al., Am. J. Physiol., 2000, 278, (4, Pt. 1), E656-E662 ).
  • PKC inhibitors are useful in treating cardiovascular ischemia and improving cardiac function following ischemia ( Muid, R. E., et al., FEBS Lett., 1990, 293, 169-172 ; Sonoki,, H. et al., Kokyu-To Junkan, 1989, 37, 669-674 ). Elevated PKC levels have been correlated with an increased platelet function response to agonists ( Bastyr III, E. J. and Lu, J., Diabetes, 1993, 42, (Suppl. 1) 97A ). PKC has been implicated in the biochemical pathway in the platelet-activating factor (PAF) modulation of microvascular permeability ( Kobayashi, et al., Amer. Phys.
  • PAF platelet-activating factor
  • PKC inhibitors affect agonist-induced aggregation in platelets ( Toullec, D., et al., J. Biol. Chem., 1991, 266, 15771-15781 ). Accordingly, PKC inhibitors may be indicated for use in treating cardiovascular disease, ischemia, thrombotic conditions, atherosclerosis and restenosis.
  • PKC- ⁇ -II activation of the PKC- ⁇ -II isoform plays an important role in diabetic vascular complications such as retinopathy ( Ishii, H., et al., Science, 1996, 272, 728-731 ) and PKC ⁇ has been implicated in development of the cardiac hypertrophy associated with heart failure ( X. Gu, et al., Circ. Res., 1994, 75, 926 ; R. H. Strasser, et al., Circulation, 1996, 94, 1551 ).
  • Overexpression of cardiac PKC ⁇ II in transgenic mice caused cardiomyopathy involving hypertrophy, fibrosis and decreased left ventricular function ( H. Wakasaki, et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 9320 ).
  • PKC inhibitors block inflammatory responses such as the neutrophil oxidative burst, CD3 down-regulation in T-lymphocytes and phorbol-induced paw edema ( Twoemy, B., et al., Biochem. Biophys. Res. Commun., 1990, 171, 1087-1092 ; Mulqueen, M. J., et al. Agents Actions, 1992, 37, 85-89 ).
  • PKC ⁇ has an essential role in the degranulation of bone marrow-derived mast cells, thus affecting cell capacity to produce IL-6 (Interleukin-6) ( Nechushtan, H., et al., Blood, 2000 (March), 95, 5, 1752-1757 ).
  • PKC plays a role in enhanced ASM (Airway Smooth Muscle) cell growth in rat models of two potential risks for asthma: hyperresponsiveness to contractile agonists and to growth stimuli ( Ren, S, et al., Am. J. Physiol., 2000, 278, (4, Pt. 1), E656-E662 ).
  • ASM Airway Smooth Muscle
  • PKC ⁇ -1 overexpression augments an increase in endothelial permeability, suggesting an important function in the regulation of the endothelial barrier ( Nagpala, P.G., et al., J. Cell Physiol., 1996, 2, 249-55 ).
  • PKC ⁇ mediates activation of neutrophil NADPH oxidase by PMA and by stimulation of Fc ⁇ receptors in neutrophils ( Dekker, L.V., et al., Biochem. J., 2000, 347, 285-289 ). Thus, PKC inhibitors may be indicated for use in treating inflammation and asthma.
  • PKC may be useful in treating or ameliorating certain immunological disorders. While one study suggests that HCMV (Human Cytomegalovirus) inhibition is not correlated with PKC inhibition ( Slater, M.J., et al., Biorg. & Med. Chem., 1999, 7, 1067-1074 ), another study showed that the PKC signal transduction pathway synergistically interacted with the cAMP-dependent PKA pathway to activate or increase HIV-1 transcription and viral replication and was abrogated with a PKC inhibitor ( Rabbi, M.F., et al., Virology, 1998 (June 5), 245, 2, 257-69 ). Therefore, an immunological disorder may be treated or ameliorated as a function of the affected underlying pathway's response to up-or down-regulation of PKC.
  • HCMV Human Cytomegalovirus
  • PKC ⁇ deficiency also results in an immunodeficiency characterized by impaired humoral immune responses and a reduced B cell response, similar to X-linked immunodeficiency in mice, playing an important role in antigen receptor-mediated signal transduction ( Leitges, M., et al., Science (Wash., D.C.), 1996, 273, 5276, 788-789 ). Accordingly, transplant tissue rejection may be ameliorated or prevented by suppressing the immune response using a PKC ⁇ inhibitor.
  • Abnormal activity of PKC has been linked to dermatological disorders characterized by abnormal proliferation of keratinocytes, such as psoriasis ( Horn, F., et al., J. Invesf. Dermatol., 1987, 88, 220-222 ; Raynaud, F. and Evain-Brion, D., Br. J. Dermatol., 1991, 124, 542-546 ).
  • PKC inhibitors have been shown to inhibit keratinocyte proliferation in a dose-dependent manner ( Hegemann, L., et al., Arch. Dermatol. Res., 1991, 283, 456-460 ; Bollag, W. B., et al., J. Invest. Dermatol., 1993, 100, 240-246 ).
  • PKC activity has been associated with cell growth, tumor promotion and cancer ( Rotenberg, S. A. and Weinstein, I. B., Biochem. Mol. Aspects Sel. Cancer, 1991, 1, 25-73 ; Ahmad, et al., Molecular Pharmacology, 1993, 43, 858-862 ); PKC inhibitors are known to be effective in preventing tumor growth in animals ( Meyer, T., et al., lnt. J. Cancer, 1989, 43, 851-856 ; Akinagaka, S., et al., Cancer Res., 1991, 51, 4888-4892 ).
  • PKC ⁇ -1 and ⁇ -2 expression in differentiated HD3 colon carcinoma cells blocked their differentiation, enabling them to proliferate in response to basic FGF (Fibroblast Growth, Factor) like undifferentiated cells, increasing their growth rate and activating several MBP (Myelin-Basic Protein) kinases, including p57 MAP (Mitogen-Activated Protein) kinase ( Sauma, S., et al., Cell Growth Differ., 1996, 7, 5, 587-94 ).
  • PKC ⁇ inhibitors having an additive therapeutic effect in combination with other anti-cancer agents, inhibited the growth of lymphocytic leukemia cells ( Konig, A., et al., Blood, 1997, 90, 10, Suppl. 1 Pt.
  • PKC inhibitors enhanced MMC (Mitomycin-C) induced apoptosis in a time-dependent fashion in a gastric cancer cell-line, potentially indicating use as agents for chemotherapy-induced apoptosis ( Danso, D., et al., Proc. Am. Assoc. Cancer Res., 1997, 38, 88 Meet., 92 ). Therefore, PKC inhibitors may be indicated for use in ameliorating cell and tumor growth, in treating or ameliorating cancers (such as leukemia or colon cancer) and as adjuncts to chemotherapy.
  • MMC Mitomycin-C
  • cancers such as leukemia or colon cancer
  • PKC ⁇ (by enhancing cell migration) may mediate some proangiogenic effects of PKC activation while PKC ⁇ may direct antiangiogenic effects of overall PKC activation (by inhibiting cell growth and proliferation) in capillary endothelial cells, thus regulating endothelial proliferation and angiogenesis ( Harrington, E.O., et al., J. Biol. Chem., 1997, 272, 11, 7390-7397 ).
  • PKC inhibitors inhibit cell growth and induce apoptosis in human glioblastoma cell lines, inhibit the growth of human astrocytoma xenografts and act as radiation sensitizers in glioblastoma cell lines ( Begemann, M., et al., Anticancer Res. (Greece), 1998 (Jul-Aug), 18, 4A, 2275-82 ).
  • PKC inhibitors, in combination with other anti-cancer agents are radiation and chemosensitizers useful in cancer therapy ( Teicher, B.A., et al., Proc. Am. Assoc. Cancer Res., 1998, 39, 89 Meet., 384 ).
  • PKC ⁇ inhibitors by blocking the MAP kinase signal transduction pathways for VEGF (Vascular Endothelial Growth Factor) and bFGF (basic Fibrinogen Growth Factor) in endothelial cells, in a combination regimen with other anti-cancer agents, have an anti-angiogenic and antitumor effect in a human T98G glioblastoma multiforme xenograft model ( Teicher, B.A., et al., Clinical Cancer Research, 2001 (March), 7, 634-640 ). Accordingly, PKC inhibitors may be indicated for use in ameliorating angiogenesis and in treating or ameliorating cancers (such as breast, brain, kidney, bladder, ovarian or colon cancers) and as adjuncts to chemotherapy and radiation therapy.
  • cancers such as breast, brain, kidney, bladder, ovarian or colon cancers
  • PKC activity plays a central role in the functioning of the central nervous system (CNS) ( Huang, K. P., Trends Neurosci., 1989, 12, 425-432 ) and PKC is implicated in Alzheimer's disease ( Shimohama, S., et al., Neurology, 1993, 43, 1407-1413 ) and inhibitors have been shown to prevent the damage seen in focal and central ischemic brain injury and brain edema ( Hara, H., et al., J. Cereb. Blood Flow Metab., 1990, 10, 646-653 ; Shibata, S., et al., Brain Res., 1992, 594, 290-294 ). Accordingly, PKC inhibitors may be indicated for use in treating Alzheimer's disease and in treating neurotraumatic and ischemia-related diseases.
  • PKC ⁇ as a component of the phosphoinositide 2 nd messenger system
  • muscarinic acetylcholine receptor expression in an amygdala-kindled rat model has been associated with epilepsy, serving as a basis for the rat's permanent state of hyperexcitability ( Beldhuis, H.J.A., et al., Neuroscience, 1993, 55, 4, 965-73 ). Therefore, PKC inhibitors may be indicated for use in treating epilepsy.
  • PKC has demonstrated a role in the pathology of conditions such as, but not limited to, cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders.
  • Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase composed of two isoforms ( ⁇ and ⁇ ) which are encoded by distinct genes.
  • GSK-3 is one of several protein kinases which phosphorylate glycogen synthase (GS) ( Embi, et al., Eur. J. Biochem, 1980, 107, 519-527 ).
  • the ⁇ and ⁇ isoforms have a monomeric structure of 49 and 47kD respectively and are both found in mammalian cells.
  • Type II diabetes or Non-Insulin Dependent Diabetes Mellitus, NIDDM
  • NIDDM Non-Insulin Dependent Diabetes Mellitus
  • Hyperglycemia is due to insulin resistance in the liver, muscle and other tissues coupled with inadequate or defective secretion of insulin from pancreatic islets.
  • Skeletal muscle is the major site for insulin-stimulated glucose uptake and in this tissue glucose removed from the circulation is either metabolised through glycolysis and the TCA (tricarboxylic acid) cycle or stored as glycogen.
  • Muscle glycogen deposition plays the more important role in glucose homeostasis and Type II diabetic subjects have defective muscle glycogen storage.
  • the stimulation of glycogen synthesis by insulin in skeletal muscle results from the dephosphorylation and activation of glycogen synthase ( Villar-Palasi C.
  • GSK-3 is responsible for phosphorylation and deactivation of GS, while glycogen bound protein phosphatase 1 (PP1 G) dephosphorylates and activates GS. Insulin both inactivates GSK-3 and activates PP1 G ( Srivastava A.K. and Pandey S.K., Mol. and Cellular Biochem., 1998, 182, 135-141 ).
  • GSK-3 ⁇ and constitutively active GSK-3 ⁇ (S9A, S9e) mutants in HEK-293 cells resulted in suppression of glycogen synthase activity ( Eldar-Finkelman, et al., PNAS, 1996, 93, 10228-10233 ) and overexpression of GSK-3 ⁇ in CHO cells, expressing both insulin receptor and insulin receptor substrate 1 (IRS-1) resulted in impairment of insulin action ( Eldar-Finkelman and Krebs, PNAS, 1997, 94, 9660-9664 ).
  • GSK-3 ⁇ knockout mouse Studies on fibroblasts from the GSK-3 ⁇ knockout mouse indicate that inhibition of GSK-3 may be useful in treating inflammatory disorders or diseases through the negative regulation of NFkB activity ( Hoeflich K. P., et al., Nature, 2000, 406, 86-90 ).
  • GSK-3 In addition to modulation of glycogen synthase activity, GSK-3 also plays an important role in the CNS disorders. GSK-3 inhibitors may be of value as neuroprotectants in the treatment of acute stroke and other neurotraumatic injuries ( Pap and Cooper, J. Biol. Chem., 1998, 273, 19929-19932 ). Lithium, a low mM inhibitor of GSK-3, has been shown to protect cerebellar granule neurons from death ( D'Mello, et al., Exp. Cell Res., 1994, 211, 332-338 ) and chronic lithium treatment has demonstrable efficacy in the middle cerebral artery occlusion model of stroke in rodents ( Nonaka and Chuang, Neuroreport, 1998, 9(9), 2081-2084 ).
  • Tau and ⁇ -catenin, two known in vivo substrates of GSK-3, are of direct relevance in consideration of further aspects of the value of GSK-3 inhibitors in relation to treatment of chronic neurodegenerative conditions.
  • Tau hyperphosphorylation is an early event in neurodegenerative conditions such as Alzheimer's disease and is postulated to promote microtubule disassembly.
  • Lithium has been reported to reduce the phosphorylation of tau, enhance the binding of tau to microtubules and promote microtubule assembly through direct and reversible inhibition of GSK-3 ( Hong M. et al J. Biol. Chem., 1997, 272(40), 25326-32 ).
  • ⁇ -catenin is phosphorylated by GSK-3 as part of a tripartite axin protein complex resulting in ⁇ -catenin degradation ( Ikeda, et al., EMBO J., 1998, 17, 1371-1384 ). Inhibition of GSK-3 activity is involved in the stabilization of catenin hence promotes ⁇ -catenin-LEF-1/TCF transcriptional activity ( Eastman, Grosschedl, Curr. Opin. Cell Biol., 1999, 11, 233 ). Studies have also suggested that GSK-3 inhibitors may also be of value in treatment of schizophrenia ( Cotter D., et al.
  • GSK-3 inhibitors could have further therapeutic utility in the treatment of diabetes, dermatological disorders, inflammatory diseases and central nervous system disorders.
  • Embodiments of the method of the present invention include a method for treating or ameliorating a kinase or dual-kinase mediated disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an instant compound or pharmaceutical composition thereof.
  • the therapeutically effective amount of the compounds of Formula (I) exemplified in such a method is from about 0.001 mg/kg/day to about 300 mg/kg/day.
  • Embodiments of the present invention include the use of a compound of Formula (I) for the preparation of a medicament for treating or ameliorating a kinase or dual-kinase mediated disorder in a subject in need thereof.
  • an individual compound of the present invention or a pharmaceutical composition thereof can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
  • Embodiments of the present method include a compound or pharmaceutical composition thereof advantageously co-administered in combination with other agents for treating or ameliorating a kinase or dual-kinase mediated disorder.
  • a compound of Formula (I) or pharmaceutical composition thereof may be used in combination with other agents, especially insulin or antidiabetic agents including, but not limited to, insulin secretagogues (such as sulphonylureas), insulin sensitizers including, but not limited to, glitazone insulin sensitizers (such as thiazolidinediones) or biguanides or ⁇ glucosidase inhibitors.
  • the combination product comprises co-administration of a compound of Formula (I) or pharmaceutical composition thereof and an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder, the sequential administration of a compound of Formula (I) or pharmaceutical composition thereof and an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder, administration of a pharmaceutical composition containing a compound of Formula (I) or pharmaceutical composition thereof and an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder or the essentially simultaneous administration of a separate pharmaceutical composition containing a compound of Formula (I) or pharmaceutical composition thereof and a separate pharmaceutical composition containing an additional agent for treating or ameliorating a kinase or dual-kinase mediated disorder.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
  • a compound of Formula (I) is therapeutically effective for certain kinase or dual-kinase mediated disorders based on the modulation of the disorder by selective kinase or dual-kinase inhibition.
  • the usefulness of a compound of Formula (I) as a selective kinase or dual-kinase inhibitor can be determined according to the methods disclosed herein and the scope of such use includes use in one or more kinase or dual-kinase mediated disorders.
  • kinase or dual-kinase mediated disorders includes, and is not limited to, cardiovascular diseases, diabetes, diabetes-associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and CNS disorders.
  • Cardiovascular diseases include, and are not limited to, acute stroke, heart failure, cardiovascular ischemia, thrombosis, atherosclerosis, hypertension, restenosis, retinopathy of prematurity or age-related macular degeneration.
  • Diabetes includes insulin dependent diabetes or Type II non-insulin dependent diabetes mellitus.
  • Diabetes-associated disorders include, and are not limited to, impaired glucose tolerance, diabetic retinopathy, proliferative retinopathy, retinal vein occlusion, macular edema, cardiomyopathy, nephropathy or neuropathy.
  • Inflammatory diseases include, and are not limited to, vascular permeability, inflammation, asthma, rheumatoid arthritis or osteoarthritis.
  • Immunological disorders include, and are not limited to, transplant tissue rejection, HIV-1 or immunological disorders treated or ameliorated by PKC modulation. Dermatological disorders include, and are not limited to; psoriasis, hair loss or baldness. Oncological disorders include, and are not limited to, cancers or tumor growth (such as breast, brain, kidney, bladder, ovarian or colon cancer or leukemia), proliferative angiopathy and angiogenesis; and, includes use for compounds of Formula (I) as an adjunct to chemotherapy and radiation therapy.
  • Dermatological disorders include, and are not limited to; psoriasis, hair loss or baldness.
  • Oncological disorders include, and are not limited to, cancers or tumor growth (such as breast, brain, kidney, bladder, ovarian or colon cancer or leukemia), proliferative angiopathy and angiogenesis; and, includes use for compounds of Formula (I) as an adjunct to chemotherapy and radiation therapy.
  • CNS disorders include, and are not limited to, chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions (such as dementia or Alzheimer's disease), mood disorders (such as schizophrenia), manic depression or neurotraumatic, cognitive decline and ischemia-related diseases ⁇ as a result of head trauma (from acute ischemic stroke, injury or surgery) or transient ischemic stroke (from coronary bypass surgery or other transient ischemic conditions) ⁇ .
  • a method of treating or ameliorating a disorder selected from the group consisting of diabetes-associated disorders, dermatological disorders, oncological disorders and central nervous system disorders comprising administering to a subject in need of treatment a therapeutically effective amount of a compound of Formula (I): wherein
  • a compound may be administered to a subject in need of treatment by any conventional route of administration including, but not limited to oral, nasal, sublingual, ocular, transdermal, rectal, vaginal and parenteral (i.e. subcutaneous, intramuscular, intradermal, intravenous etc.).
  • one or more compounds of Formula (I) or salt thereof as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral).
  • a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration (e.g. oral or parenteral).
  • Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers may be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Brita in.
  • any of the usual pharmaceutical media or excipients may be employed.
  • suitable carriers and additives include but are not limited to pharmaceutically acceptable wetting agents, dispersants, flocculation agents, thickeners, pH control agents (i.e. buffers), osmotic agents, coloring agents, flavors, fragrances, preservatives (i.e. to control microbial growth, etc.) and a liquid vehicle may be employed. Not all of the components listed above will be required for each liquid dosage form.
  • suitable carriers and additives include but are not limited to diluents, granulating agents, lubricants, binders, glidants, disintegrating agents and the like. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated, gelatin coated, film coated or enteric coated by standard techniques.
  • the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.
  • the pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.001 mg to about 300 mg (preferably, from about 0.01 mg to about 100 mg; and, more preferably, from about 0.1 mg to about 30 mg) and may be given at a dosage of from about 0.001 mg/kg/day to about 300 mg/kg/day (preferably, from about 0.01 mg/kg/day to about 100 mg/kg/day; and, more preferably, from about 0.1 mg/kg/day to about 30 mg/kg/day).
  • the dosage form will contain a pharmaceutically acceptable carrier containing between about 0.01 mg and 100 mg; and, more preferably, between about 5 mg and 50 mg of the compound; and, may be constituted into any form suitable for the mode of administration selected.
  • the dosages may be varied depending upon the requirement of the subjects, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
  • compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, lozenges, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories for administration by oral, intranasal, sublingual, intraocular, transdermal, parenteral, rectal, vaginal, inhalation or insufflation means.
  • the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and glidants.
  • a pharmaceutical carrier e.g. conventional tableting ingredients such as diluents, binders, adhesives, disintegrants, lubricants, antiadherents and glidants.
  • Suitable diluents include, but are not limited to, starch (i.e.
  • corn, wheat, or potato starch which may be hydrolized), lactose (granulated, spray dried or anhydrous), sucrose, sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, about 0.1 to 0.2 weight percent cornstarch and magnesium stearate), dextrose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e. AVICEL TM microcrystalline cellulose available from FMC Corp.), dicalcium phosphate, calcium sulfate dihydrate, calcium lactate trihydrate and the like.
  • sucrose sucrose-based diluents (confectioner's sugar; sucrose plus about 7 to 10 weight percent invert sugar; sucrose plus about 3 weight percent modified dextrins; sucrose plus invert sugar, about 4 weight percent invert sugar, about 0.1
  • Suitable binders and adhesives include, but are not limited to acacia gum, guar gum, tragacanth gum, sucrose, gelatin, glucose, starch, and cellulosics (i.e. methylcellulose, sodium carboxymethycellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like), water soluble or dispersible binders (i.e. alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose (i.e.
  • TYLOSE TM available from Hoechst Celanese
  • polyethylene glycol polysaccharide acids
  • bentonites polyvinylpyrrolidone
  • polymethacrylates polymethacrylates and pregelatinized starch
  • Suitable disintegrants include, but are not limited to, starches (corn, potato, etc.), sodium starch glycolates, pregelatinized starches, clays (magnesium aluminum silicate), celluloses (such as crosslinked sodium carboxymethylcellulose and microcrystalline cellulose), alginates, pregelatinized starches (i.e. corn starch, etc.), gums (i.e.
  • Suitable lubricants and antiadherents include, but are not limited to, stearates (magnesium, calcium and sodium), stearic acid, talc waxes, stearowet, boric acid, sodium chloride, DL-leucine, carbowax 4000, carbowax 6000, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate and the like.
  • Suitable glidants include, but are not limited to, talc, cornstarch, silica (i.e. CAB-O-SIL TM silica available from Cabot, SYLOID TM silica available from W.R. Grace/Davison and AEROSIL TM silica available from Degussa) and the like.
  • silica i.e. CAB-O-SIL TM silica available from Cabot, SYLOID TM silica available from W.R. Grace/Davison and AEROSIL TM silica available from Degussa
  • Sweeteners and flavorants may be added to chewable solid dosage forms to improve the palatability of the oral dosage form. Additionally, colorants and coatings may be added or applied to the solid dosage form for ease of identification of the drug or for aesthetic purposes.
  • These carriers are formulated with the pharmaceutical active to provide an accurate, appropriate dose of the pharmaceutical active with a therapeutic release profile.
  • these carriers are mixed with the pharmaceutical active to form a solid preformulation composition containing a homogeneous mixture of the pharmaceutical active of the present invention, or a pharmaceutically acceptable salt thereof.
  • the preformulation will be formed by one of three common methods: (a) wet granulation, (b) dry granulation and (c)dry blending.
  • wet granulation dry granulation
  • dry blending dry blending.
  • this solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from about 0.1 mg to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills containing the novel compositions may also be formulated in multilayer tablets or pills to provide a sustained or provide dual-release products.
  • a dual release tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric materials such as shellac, cellulose acetate (i.e.
  • Sustained release tablets may also be made by film coating or wet granulation using slightly soluble or insoluble substances in solution (which for a wet granulation acts as the binding agents) or low melting solids a molten form (which in a wet granulation may incorporate the active ingredient).
  • These materials include natural and synthetic polymers waxes, hydrogenated oils, fatty acids and alcohols (i.e.
  • esters of fatty acids metallic soaps and other acceptable materials that can be used to granulate, coat, entrap or otherwise limit the solubility of an active ingredient to achieve a prolonged or sustained release product.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, but are not limited to aqueous solutions, suitably flavored syrups, aqueous or oil suspensions and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable suspending agents for aqueous suspensions include synthetic and natural gums such as, acacia, agar, alginate (i.e.
  • cellulosics such as sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose and combinations thereof
  • synthetic polymers such as polyvinyl pyrrolidone, carbomer
  • Suitable surfactants include but are not limited to sodium docusate, sodium lauryl sulfate, polysorbate, octoxynol-9, nonoxynol-10, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxamer 188, polyoxamer 235 and combinations thereof.
  • Suitable deflocculating or dispersing agent include pharmaceutical grade lecithins.
  • Suitable flocculating agent include but are not limited to simple neutral electrolytes (i.e. sodium chloride, potassium, chloride and the like), highly charged insoluble polymers and polyelectrolyte species, water soluble divalent or trivalent ions (i.e.
  • Suitable preservatives include but are not limited to parabens (i.e. methyl, ethyl, n -propyl and n -butyl), sorbic acid, thimerosal, quaternary ammonium salts, benzyl alcohol, benzoic acid, chlorhexidine gluconate, phenylethanol and the like.
  • parabens i.e. methyl, ethyl, n -propyl and n -butyl
  • sorbic acid thimerosal, quaternary ammonium salts
  • benzyl alcohol benzoic acid
  • chlorhexidine gluconate phenylethanol and the like.
  • the liquid vehicle that is used in a particular dosage form must be compatible with the suspending agent(s).
  • nonpolar liquid vehicles such as fatty esters and oils liquid vehicles are best used with suspending agents such as low HLB (Hydrophile-Lipophile Balance) surfactants, stearalkonium hectorite, water insoluble resins, water insoluble film forming polymers and the like.
  • suspending agents such as low HLB (Hydrophile-Lipophile Balance) surfactants, stearalkonium hectorite, water insoluble resins, water insoluble film forming polymers and the like.
  • polar liquids such as water, alcohols, polyols and glycols are best used with suspending agents such as higher HLB surfactants, clays silicates, gums, water soluble cellulosics, water soluble polymers and the like.
  • sterile suspensions and solutions are desired. Liquid forms useful for parenteral administration include sterile solutions, emulsions and suspensions. Isotonic preparations which generally contain suitable preservatives are employed when intrave
  • compounds of the present invention can be administered in an intranasal dosage form via topical use of suitable intranasal vehicles or via transdermal skin patches, the composition of which are well known to those of ordinary skill in that art.
  • suitable intranasal vehicles or via transdermal skin patches, the composition of which are well known to those of ordinary skill in that art.
  • transdermal delivery system the administration of a therapeutic dose will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • Liposome delivery systems such as small unilamellar vesicles, large unilamellar vesicles, multilamellar vesicles and the like.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, phosphatidylcholines and the like.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include, but are not limited to polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxy-ethylaspartamidephenol, or polyethyl eneoxidepolylysine substituted with palmitoyl residue.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, to homopolymers and copolymers (which means polymers containing two or more chemically distinguishable repeating units) of lactide (which includes lactic acid d-, 1- and meso lactide), glycolide (including glycolic acid), ⁇ -caprolactone, p-dioxanone (1,4-dioxan-2-one), trimethylene carbonate (1,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, ⁇ -valerolactone, ⁇ -butyrolactone, ⁇ -butyrolactone, ⁇ -decalactone, hydroxybutyrate, hydroxyvalerate, 1,4-dioxepan-2-one (including its dimer 1,5,8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-2-one
  • Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever treating or ameliorating a kinase or dual-kinase mediated disorder is required for a subject in need thereof; in particular, whenever treating or ameliorating a kinase disorder mediated by selective inhibition of a kinase selected from protein kinase C or glycogen synthase kinase-3 is required; and, whenever treating or ameliorating a kinase disorder mediated by dual inhibition of at least two kinases selected from protein kinase C and glycogen synthase kinase-3 is required; and, more particularly, whenever treating or ameliorating a kinase disorder mediated by selective inhibition of a kinase selected from protein kinase C ⁇ , protein kinase C ⁇ -I, protein kinase C ⁇ -II, protein kinase C ⁇ or
  • the daily dose of a pharmaceutical composition of the present invention may be varied over a wide range from about 0.7 mg to about 21,000 mg per 70 kilogram (kg) adult human per day; preferably in the range of from about 7 mg to about 7,000 mg per adult human per day; and, more preferably, in the range of from about 7 mg to about 2,100 mg per adult human per day.
  • the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
  • a therapeutically effective amount of the drug is ordinarily supplied at a dosage level of from about 0.001 mg/kg to about 300 mg/kg of body weight per day.
  • the range is from about 0.1 mg/kg to about 100 mg/kg of body weight per day; and, most preferably, from about 0.1 mg/kg to about 30 mg/kg of body weight per day.
  • compounds of the present invention may be administered in a single daily dose or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • Optimal dosages to be administered may be readily determined by those skilled in the art and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level.
  • ATP adenosinetriphosphate
  • BSA bovine serum albumin
  • DMF N, N-dimethylformamide
  • DMSO dimethylsulfoxide
  • EGTA ethylenebis(oxyethylenenitrilo)tetraacetic acid
  • h hour
  • TCA trichloroacetic acid
  • THF tetrahydrofuran
  • TFA trifluoroacetic acid
  • TMSCHN 2 trimethylsilyldiazomethane
  • Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated more particularly in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.
  • the substituted indole Compound AA1 was arylated with an appropriately substituted aryl or heteroaryl halide and a base such as cesium or potassium carbonate and copper oxide in a dipolar aprotic solvent such as DMF to give Compound AA2.
  • Compound AA2 was acylated with oxalyl chloride in an aprotic solvent such as diethyl ether or DCM and quenched with sodium methoxide to afford an intermediate glyoxylic ester Compound AA3.
  • Compound AA5 was prepared from Compound AA1 via acylation with oxalyl chloride followed by treatment with sodium methoxide to afford glyoxylic ester Compound AA4 which was then alkylated with an appropriate alkylating agent under basic conditions.
  • the substituted 3-indazoleacetic acid Compound AA7 was prepared from aldehyde Compound AA6 by reaction with malonic acid and ammonium formate followed by reductive cyclization under basic conditions ( B. Mylari, et al., J. Med. Chem., 1992, 35, 2155 ).
  • the acid Compound AA7 was coupled with ammonium hydroxide in an aprotic solvent such as DCM or acetonitrile using a dehydrating agent like dicyclohexyl carbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) to give amide Compound AA8, which was treated with an appropriate alkylating agent AA9 in the presence of a base such as sodium hydride to afford indazole Compound AA10 as a mixture of N 1-alkylated (major) and N 2-alkylated (minor) products.
  • a dehydrating agent like dicyclohexyl carbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT)
  • DCC dicyclohexyl carbodiimide
  • HOBT 1-hydroxybenzotriazole
  • the ester Compound AA3 or AA5 may be reacted with the amide Compound AA10 stirred in an aprotic solvent such as THF with ice bath cooling and a base, such as potassium tert -butoxide or sodium hydride, to give Compound AA11.
  • Compound AA11 was converted its mesylate AA12 by treating with methanesulfonic anhydride.
  • Treatment of AA12 with an NH-containing heteroaryl in the presence of a base afforded the target Compound AA13.
  • N 1-alkylated (major) and N 2-alkylated (minor) products can be separated by chromatography.
  • Indazole amide Compound AA15 was prepared via alkylation of AA8 with a heteroaryl-containing alkylating agent AA14 in the presence of a base, such as potassium carbonate or sodium hydride.
  • the amide AA15 may be reacted with the ester Compound AA3 or AA5 in an aprotic solvent such as THF with ice bath cooling and a base, such as potassium tert -butoxide or sodium hydride, to give product AA16.
  • Preparative TLC was performed with Analtech 1000- ⁇ m silica gel GF plates. Flash column chromatography was conducted with flash column silica gel (40-63 ⁇ m) and column chromatography was conducted with standard silica gel.
  • HPLC separations were carried out on three Waters PrepPak ® Cartridges (25 x 100 mm, Bondapa ® C18, 15-20 ⁇ m, 125 A) connected in series; detection was at 254 nm on a Waters 486 UV detector.
  • Analytical HPLC was carried out on a Supelcosil ABZ+PLUS column (5 cm x 2.1 mm), with detection at 254 nm on a Hewlett Packard 1100 UV detector. Microanalysis was performed by Robertson Microlit Laboratories, Inc.
  • 100 mg of Compound 14 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
  • kinases selected from protein kinase C and glycogen synthase kinase-3 were determined using the following procedures.
  • PKC isoforms ⁇ , ⁇ -II or ⁇ were added to a reaction mixture that contained 20 mM HEPES, (pH 7.4), 940 ⁇ M CaCl 2 , 10 mM MgCl 2 , 1 mM EGTA. 100 ⁇ g/mL phosphatidylserine, 20 ⁇ g/mL diacylglycerol, 30 ⁇ M ATP, 1 ⁇ Ci ( 33 P)ATP and 200 ⁇ g/mL histone III. The reaction was incubated for 10 min at 30°C. Reactions were terminated by TCA precipitation and spotting on Whatman P81 filters. Filters were washed in 75 mM phosphoric acid and the radioactivity quantified by liquid scintillation counting.
  • Table 1 shows the biological activity in the histone based assay as IC 50 values ( ⁇ M) for representative compounds of the present invention.
  • Table 1 PKC Activity (IC 50 ⁇ M, Histone Based Assay) Cpd Alpha Beta II Gamma 1 0.567 0.015 0.476 2 1.212 0.046 0.395 3 2.349 0.045 1.010 4 0.505 0.035 0.544 5 0.542 0.025 1.698 6 0.326 0.022 1.106 7 0.451 0.044 1.447 8 1.039 0.052 4.301 9 2.976 0.041 1.421 10 0.424 0.009 0.602 11 1.359 0.123 1.934 12 0.554 0.069 0.226
  • test compound was added to a reaction mixture containing Protein phosphatase inhibitor-2 (PPI-2) (Calbiochem) (45 ng), rabbit GSK-3 ⁇ protein (New England Biolabs) (0.75 units) and 33 P-ATP (1 ⁇ Ci) in 50 mM Tris-HCl (pH 8.0), 10 mM MgCl 2 , 0.1 % BSA, 1 mM DTT and 100 ⁇ M Sodium Vanadate. The mixture was reacted for 90 minutes at 30°C to allow phosphorylation of the PPI-2 protein and then the protein in the reaction was precipitated using 10 % TCA.
  • PPI-2 Protein phosphatase inhibitor-2
  • the precipitated protein was collected on filter plates (MultiScreen-DV/Millipore), which were subsequently washed. Finally, the radioactivity was quantified using a TopCount Scintillation Counter (Packard). GSK-3 inhibitory compounds resulted in less phosphorylated PPI-2 and thus a lower radioactive signal in the precipitated protein. Staurosporine or Valproate, known inhibitors of GSK-3 ⁇ , were used as a positive control for screening.
  • Table 2 shows the biological activity in the GSK-3 ⁇ assay as IC 50 values ( ⁇ M) for representative compounds of the present invention.
  • Table 2 GSK-3 ⁇ Assay Activity (IC 50 ⁇ M) Cpd GSK-3 ⁇ 1 0.004 2 0.003 3 0.004 4 0.004 5 0.776 6 29%@1 ⁇ M 7 0.027 8 0.034 9 0.005 10 0.005 11 0.005 12 0.107

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
EP04754066A 2003-06-13 2004-06-01 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors Expired - Lifetime EP1654255B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47851603P 2003-06-13 2003-06-13
PCT/US2004/017375 WO2005000836A1 (en) 2003-06-13 2004-06-01 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
EP1654255A1 EP1654255A1 (en) 2006-05-10
EP1654255B1 true EP1654255B1 (en) 2008-08-27

Family

ID=33551833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04754066A Expired - Lifetime EP1654255B1 (en) 2003-06-13 2004-06-01 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

Country Status (22)

Country Link
US (1) US7439363B2 (zh)
EP (1) EP1654255B1 (zh)
JP (1) JP2007500748A (zh)
KR (1) KR20060021890A (zh)
CN (1) CN1832940A (zh)
AT (1) ATE406365T1 (zh)
AU (1) AU2004251178A1 (zh)
BR (1) BRPI0411366A (zh)
CA (1) CA2529353A1 (zh)
CO (1) CO5650246A2 (zh)
CR (1) CR8148A (zh)
DE (1) DE602004016174D1 (zh)
EA (1) EA200600032A1 (zh)
EC (1) ECSP056222A (zh)
ES (1) ES2311161T3 (zh)
HR (1) HRP20050991A2 (zh)
IL (1) IL172456A0 (zh)
IS (1) IS8174A (zh)
NO (1) NO20060145L (zh)
RS (1) RS20050915A (zh)
WO (1) WO2005000836A1 (zh)
ZA (1) ZA200600294B (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431166A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU2003225295A1 (en) * 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
ES2312785T3 (es) * 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
EP1611132A1 (en) * 2003-03-27 2006-01-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009510085A (ja) * 2005-09-29 2009-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼインヒビターとしての大型複素環式化合物
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR101284836B1 (ko) 2006-05-25 2013-07-10 삼성전자주식회사 이동통신시스템에서 자원 할당 맵 구성 방법
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008037266A1 (en) * 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
AU2007336338A1 (en) 2006-12-19 2008-06-26 Novartis Ag Indolylmaleimide derivatives as kinase inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2387359B1 (es) * 2011-02-25 2013-08-01 Consejo Superior De Investigaciones Científicas (Csic) Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
CN102344443A (zh) * 2011-07-15 2012-02-08 南开大学 点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103622964B (zh) * 2013-12-04 2015-09-23 李强 Trigolutesins A在治疗或预防急性心衰药物中的应用
US10220408B2 (en) * 2016-09-12 2019-03-05 The Boeing Company Variable radius print head end effector
CN108586432B (zh) * 2018-05-31 2020-08-25 温州医科大学 一种3-(吲哚-5-基)-吲唑衍生物及其应用
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
IL141080A0 (en) 1998-07-30 2002-02-10 Japan Tobacco Inc Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
EP1119548B1 (en) 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
CA2431166A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
AU2003225295A1 (en) 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
AU2003238874A1 (en) 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Bisindolyl-maleimid derivatives as kinase inhibitors
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
EP1611132A1 (en) 2003-03-27 2006-01-04 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors

Also Published As

Publication number Publication date
BRPI0411366A (pt) 2006-07-25
US20050004201A1 (en) 2005-01-06
WO2005000836A1 (en) 2005-01-06
ZA200600294B (en) 2007-04-25
AU2004251178A1 (en) 2005-01-06
IL172456A0 (en) 2006-04-10
JP2007500748A (ja) 2007-01-18
KR20060021890A (ko) 2006-03-08
NO20060145L (no) 2006-03-07
CO5650246A2 (es) 2006-06-30
RS20050915A (sr) 2008-04-04
CN1832940A (zh) 2006-09-13
HRP20050991A2 (en) 2006-09-30
ECSP056222A (es) 2006-04-19
DE602004016174D1 (de) 2008-10-09
IS8174A (is) 2005-12-09
US7439363B2 (en) 2008-10-21
CR8148A (es) 2008-09-10
ES2311161T3 (es) 2009-02-01
ATE406365T1 (de) 2008-09-15
CA2529353A1 (en) 2005-01-06
EA200600032A1 (ru) 2006-06-30
EP1654255A1 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
EP1654255B1 (en) Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
EP1513520B1 (en) Substituted pyrrolines as kinase inhibitors
US6987110B2 (en) Substituted pyrrolines as kinase inhibitors
EP1362047B1 (en) Indazolyl-substituted pyrroline compounds as kinase inhibitors
EP1506192B1 (en) Substituted pyrroline kinase inhibitors
US20090093634A1 (en) Substituted pyrroline kinase inhibitors
MXPA05013655A (en) Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL

RAX Requested extension states of the european patent have changed

Extension state: AL

Payment date: 20060113

17Q First examination report despatched

Effective date: 20070313

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004016174

Country of ref document: DE

Date of ref document: 20081009

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2311161

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090127

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

26N No opposition filed

Effective date: 20090528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20090529

Year of fee payment: 6

Ref country code: GB

Payment date: 20090527

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081127

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100226

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090601

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081128

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090602

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110101

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080827